^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
utidelone IV (UTD1)
i
Other names: UTD1, UTD-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Biostar Technologies, Luye Group
Drug class:
Microtubule inhibitor, Tubulin polymerization promoter
Related drugs:
16h
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
Enrollment status
|
gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
3ms
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases (clinicaltrials.gov)
P2, N=120, Recruiting, Biostar Pharma, Inc. | Initiation date: Jan 2025 --> Jul 2025
Trial initiation date
|
capecitabine • utidelone IV (UTD1)
4ms
EXPRESS: Utidelone induces mechanical and cold allodynia in mice via TRPA1 activation. (PubMed, Mol Pain)
Utidelone (UTD1), an epothilone analogue recently approved in China for treating metastatic breast cancer, is recommended in conjunction with capecitabine for patients who have not responded to first-line therapies. Administration of the TRPA1 antagonist HC-030031 significantly alleviated mechanical and cold allodynia in the UTD1-induced pain model, as did two antioxidants, Mito-tempo and edaravone. This study proposes new approaches for mitigating pain caused by UTD1.
Preclinical • Journal
|
ATF4 (Activating Transcription Factor 4) • SOD2 (Superoxide Dismutase 2) • TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1)
|
capecitabine • utidelone IV (UTD1)
4ms
Utidelone induces apoptosis and autophagy in small cell lung cancer cells through the ROS/AMPK signaling pathway (PubMed, Zhonghua Zhong Liu Za Zhi)
Furthermore, the proportions of apoptosis-positive cells and p-AMPKα-positive cells in the UTD1 group were significantly higher compared to the control group, while the levels of Ki-67 positivity were significantly reduced. UTD1 inhibits SCLC cell proliferation, induces G2/M phase arrest, and promotes cell apoptosis and autophagy through the activation of the ROS/AMPK signaling pathway.
Journal
|
CCNA2 (Cyclin A2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNB1 (Cyclin B1)
|
utidelone IV (UTD1)
4ms
A Clinical Study of Utidelone Combined with Tegafur-Gimeracil-Oteracil Potassium (S-1), Anlotinib, and Sintilimab as First-Line Therapy for HER2-Negative Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma (ChiCTR2500104634)
P2, N=35, Not yet recruiting, Shanghai Changzheng Hospital; Shanghai Changzheng Hospital
New P2 trial
|
Focus V (anlotinib) • Tyvyt (sintilimab) • Teysuno (gimeracil/oteracil/tegafur) • utidelone IV (UTD1)
5ms
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
P3, N=192, Enrolling by invitation, Sun Yat-sen University
New P3 trial
|
gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
6ms
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
This treatment approach warrants further validation in a randomized clinical trial. ClinicalTrials.gov Identifier: NCT05357417.
Clinical • P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Avastin (bevacizumab) • Airuituo (bevacizumab biosimilar) • utidelone IV (UTD1)
6ms
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. (PubMed, iScience)
Clinically, UTD1 + GEM demonstrated good tolerability, high disease control rates, and favorable immunophenotypic changes. These findings suggest UTD1 triggers ICD, enhancing immune recognition of tumor cells, and highlight its potential as a therapeutic strategy for PDAC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
gemcitabine • utidelone IV (UTD1)
6ms
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients (clinicaltrials.gov)
P3, N=440, Not yet recruiting, Fudan University
New P3 trial
|
capecitabine • utidelone IV (UTD1)
11ms
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases (clinicaltrials.gov)
P2, N=120, Recruiting, Beijing Biostar Pharmaceuticals Co., Ltd.
New P2 trial
|
capecitabine • utidelone IV (UTD1)
1year
Utidelone combined with anti‑angiogenic therapy for the treatment of anthracycline/taxane‑treated and endocrine‑resistant HR+/HER2‑ refractory breast cancer with brain metastases: A case report. (PubMed, Oncol Lett)
This result was superior to the second-line treatment with nab-paclitaxel, which resulted in a PFS of 8 months and best overall response of stable disease with slight shrinkage. The present case indicates that a combination of utidelone with apatinib/anlotinib exhibited antitumor activity in a patient with HR+/HER2- mBC with BMs. Therefore, this combination offers a promising therapeutic option for the clinical treatment of patients with breast cancer and BMs.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Focus V (anlotinib) • AiTan (rivoceranib) • albumin-bound paclitaxel • utidelone IV (UTD1)
1year
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases (clinicaltrials.gov)
P2, N=118, Not yet recruiting, Beijing Biostar Pharmaceuticals Co., Ltd.
New P2 trial
|
Avastin (bevacizumab) • utidelone IV (UTD1)
Share via
